JPMorgan Chase & Co. Buys 33,078 Shares of Cryoport, Inc. (NASDAQ:CYRX)

JPMorgan Chase & Co. raised its stake in shares of Cryoport, Inc. (NASDAQ:CYRX) by 10.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 338,315 shares of the company’s stock after purchasing an additional 33,078 shares during the period. JPMorgan Chase & Co.’s holdings in Cryoport were worth $2,632,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in CYRX. LPL Financial LLC grew its stake in shares of Cryoport by 1,366.1% in the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company’s stock worth $3,398,000 after buying an additional 406,976 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in shares of Cryoport by 1,286.1% in the 4th quarter. Perkins Capital Management Inc. now owns 159,400 shares of the company’s stock valued at $1,240,000 after acquiring an additional 147,900 shares during the last quarter. Barclays PLC lifted its holdings in shares of Cryoport by 272.9% in the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock valued at $660,000 after acquiring an additional 59,582 shares during the last quarter. SG Americas Securities LLC grew its position in Cryoport by 44.8% in the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock worth $1,142,000 after acquiring an additional 45,430 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Cryoport by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock worth $8,902,000 after acquiring an additional 38,520 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Insider Transactions at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 19,830 shares of company stock valued at $118,353. Corporate insiders own 10.10% of the company’s stock.

Cryoport Price Performance

CYRX opened at $5.56 on Wednesday. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $17.41. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $277.50 million, a price-to-earnings ratio of -1.64 and a beta of 1.81. The business’s fifty day simple moving average is $5.94 and its 200-day simple moving average is $6.98.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the company earned ($0.29) earnings per share. On average, equities research analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CYRX shares. Roth Mkm reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday, April 1st. Guggenheim restated a “buy” rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. Finally, UBS Group boosted their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Cryoport presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.